Celltrion Healthcare IPO - Early Review on Key Issues
Celltrion Healthcare, which is Celltrion (068270)’s overseas sales and marketing unit, submitted the application for preliminary screening for...
356 Views
SillaJen IPO Part 3 - Competitive Strengths of Product (Pexa-Vec)
*Â In Part 3 (as below), I summarized the competitive strengths of product (Pexa-Vec).SillaJen's Pexa-Vec is an advanced liver cancer treatment...
339 Views
One World, Two Stories
Celltrion's management continues to make very optimistic projections about Remsima's US sales in 2017 despite regulatory hurdles that will limit...
289 Views
SillaJen IPO Part 2 - Growth Potential & Appropriate Valuation Level
* In Part 2 (as below), I summarized the growth potential and appropriate valuation level of SillaJen.Apparently, not many people are doubtful...
342 Views
The Chickens Are Ready to Roost
Several recent developments confirm our thesis that Inflectra's US sales in 2017 will fall far short of management's 2017 forecast. First, Pfizer's...
294 Views